Description of Lymphatic Damage in Encephalic Venous Thrombosis and Strictures in MRI a Reverse-recovery Sequence: a Pilot Study

NCT05041569 | Recruiting

• 1 other identifier: JSY_2021_12
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Inclusion (J0):

• Information
• Verification of inclusion and non-inclusion criteria
• Collection of consent
• MRI examination with injection of contrast product as part of the treatment comprising the sequences: T1 TFE 1.0 iso 3D FLAIR injected Injected elliptical venous angiography 0.4mm iso or less 3D SWIp multiecho 3D T1 injected FABIR iso without injection (added as part of care in case of suspected ASH or meningitis) FLAIR 1.0 without injection (added as part of care for suspected ASH or meningitis) T2 BFFE XD (added by search) FABIR iso injected (added by research) 3D PD T1 0.55 MSDE iso injected (added by research) Clinical information (SRM on inclusion, on discharge and at 3 months and recurrence within the year) will be collected from the patient's medical file

Conditions

Description of Local Modifications of Lymph Nodes or Bundles With the FABIR Sequence in MRI

Outcome Measures

Primary Outcomes (1)

• Using a new MRI sequence for the detection of lymph nods

  Inversion recovery pulse sequences in MRI will be used to detect lymph nods.

  1 DAY

Interventions

MRI sequences OTHER

perform additional sequences added by research

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patient presenting for imaging as part of their treatment

You may qualify if:

• Patients over 18 years of age
• Performing an MRI injected as part of care for one of the following reasons:
• suspicion of pathology likely to be associated with narrowing or obstruction of one or more venous sinuses (cerebral thrombophlebitis, tissue damage with venous extension, idiopathic HIC
• venous narrowing or obstruction proven by one of the above pathologies, requiring as part of routine care an injected MRI (search for impact, monitoring, pre-therapeutic assessment or prognosis)
• Express consent to participate in the study
• Affiliate or beneficiary of a social security scheme

You may not qualify if:

• Absolute contraindication to MRI
• Patient benefiting from a legal protection measure
• Pregnant or breastfeeding woman

Sponsors & Collaborators

• Fondation Ophtalmologique Adolphe de Rothschild: lead

Study Sites (1)

Hhopital fondation adolphe de rothschild

Paris, Paris, 75019, France

RECRUITING

Central Study Contacts

amélie YAVCHITZ

CONTACT

0148036454; ayavchitz@for.paris

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 15, 2021
• First Posted: September 13, 2021
• Study Start: December 17, 2021
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: February 18, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)